AU2006326936A1
|
|
Antibacterial agents
|
US2009023669A1
|
|
Antibacterial agents
|
AU2006299733A1
|
|
Method of drug design
|
CN101278079A
|
|
Method of drug design
|
AU2006209794A1
|
|
Classes of compounds that interact with integrins
|
CN101111243A
|
|
Classes of compounds that interact with integrins
|
CN101036057A
|
|
Selective inhibitors
|
AU2005291833A1
|
|
Selective inhibitors
|
AU2005230207A1
|
|
Biologically active compounds with anti-angiogenic properties
|
EP1732573A1
|
|
Biologically active compounds with anti-angiogenic properties
|
AU2003266858A1
|
|
Classes of compounds that interact with GPCRs
|
AU2003257259A1
|
|
Compounds that interact with kinases
|
AU2003218916A1
|
|
Disaccharides for drug discovery
|
AU2003215422A1
|
|
Anomeric derivatives of monosaccharides
|
US7541445B2
|
|
Synthetic heparin pentasaccharides
|